A Prospective, Phase 3 Study of Patients with Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
- Sponsor:
- COG
- Sponsor Study ID:
- ARST2032
- CTO #:
- 103878
- NCT Number:
- NCT05304585
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Children
- Disease Sites:
- Soft Tissue
- Study Objectives:
- To evaluate the failure free survival of patients with very low risk rhabdomyosarcoma stage 1, clinical group I, MYOD1 wildtype, TP53 when treated with 24 weeks of vincristine and dactinomycin.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Kraveka, Jacqueline, at kravekjm@musc.edu .
- Study Coordinator, Pound, Ashton, at pound@musc.edu , or please call +1 843-792-6078.
Trial opened at the following institutions:
Medical University of South Carolina